| ²é¿´: 1079 | »Ø¸´: 2 | |||||||||||||||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | |||||||||||||||
ÓÐÈË¿´µ½ÎҵĶú»Ìú³æ (³õÈëÎÄ̳)
|
[½»Á÷]
Ìì½òÒ½¿Æ´óѧ»ù´¡Ò½Ñ§ÔºÕÔÀö½ÌÊÚ¿ÎÌâ×齲ʦ¡¢²©ºó¼°¿ÆÑÐÖúÀíÕÐÆ¸
|
||||||||||||||
¿ÎÌâ×é½éÉÜ ÕÔÀö½ÌÊÚΪÌì½òÒ½¿Æ´óѧ»ù´¡Ò½Ñ§ÔºÉúÎﻯѧÓë·Ö×ÓÉúÎïѧϵ½ÌÊÚ£¬Ìì½òÊÐÌØÆ¸½ÌÊÚ£¬²©Ê¿Éúµ¼Ê¦¡£ ¿ÎÌâ×鳤ÆÚÖÂÁ¦ÓÚÁ˽âÏÂÇðÄÔ-´¹Ì壬¼××´ÏÙ£¬ÈéÏÙµÈÉñ¾ÄÚ·ÖÃÚ»·Â·ÖÐµÄÆ÷¹Ù·¢Óý£¬²¢ÒÔ´ËÍÆ½ø¶ÔÏà¹Ø¼²²¡ºÍ°©Ö¢·¢Éú»úÖÆµÄÀí½â¡£ÀûÓÃת»ùÒòСÊó¹¹½¨¸÷ÖÖÌù½üÁÙ´²ÉúÀí¼²²¡ºÍ°©Ö¢µÄ¶¯Îï¼²²¡Ä£ÐÍ£»½Òʾ²¢×·×ÙÆ÷¹Ù·¢ÓýºÍÖ×Áö·¢ÉúµÄ¹Ø¼üÆðʼϸ°ûµÄ£»ÒÔǰÆÚ·Ö×Ó»úÖÆÍÚ¾òºÍÄÉÃ×°ÐÏòÒ©ÎïµÄ¿ª·¢ÓëµÝËÍΪ»ù´¡£¬Îª°©Ö¢ÖÎÁÆÌرðÊÇÄÑÖÎÐÔ¡¢×ªÒÆÐÔ°©Ö¢µÄÖÎÁÆÌṩ°ÐÏòÐÔÓëÓÐЧÐԸߡ¢¸±×÷ÓÃСµÄÖÎÁƲßÂÔ¡£ ¿ÎÌâ×é³É¹û£º ·¢±íÔÚMolecular Cell¡¢Developmental Cell¡¢Nature Communications¡¢Development¡¢Oncogene¡¢Journal of Bone and Mineral Research¡¢ACS NanoµÈÔÓÖ¾20ÓàÆª¡£ 1. Zhang Z, Wu Y, Fu J, Yu X, Su Y, Jia S, Cheng H, Shen Y, He X, Ren K, Zheng X, Guan H, Rao F, Zhao L. (2024) Proteostatic reactivation of the developmental transcription factor TBX3 drives BRAF/MAPK-mediated tumorigenesis.Nat Commun. 15(1):4108. 2. Zhang P, Guan L, Sun W, Zhang Y, Du Y, Yuan S, Cao X, Yu Z, Jia Q, Zheng X, Meng Z, Li X, Zhao L.(2024) Targeting miR-31 represses tumourigenesis and dedifferentiation of BRAFV600E-associated thyroid carcinoma. Clin Transl Med. 14(5):e1694. 3. Su Y, Luo Y, Zhang P, Lin H, Pu W, Zhang H, Wang H, Hao Y, Xiao Y, Zhang X, Wei X, Nie S,Zhang K, Fu Q, Chen H, Huang N, Ren Y, Wu M, Chow BKC, Chen X, Jin W, Wang F, Zhao L*, Rao F*. (2023) Glucose-induced CRL4COP1-p53 axis amplifies glycometabolism to drive tumorigenesis. Mol Cell. 83(13):2316-2331.e7. 4¡¢Zhang P, Guan H, Yuan S, Cheng H, Zhang Z, Zheng J, Yu Y, Meng Z, Zheng X, Zhao L*. (2022) Targeting myeloid derived suppressor cells reverts immune suppression and sensitizes BRAF-mutant papillary thyroid cancer to MAPK inhibitors. Nat Commun. 13(1):1588 5¡¢Yuan S, Zhang P, Wen L, Jia S, Wu Y, Zhang Z, Guan L, Yu Z, Zhao L*. (2021) miR-22 promotes stem cell traits via activating Wnt/¦Â-catenin signaling in cutaneous squamous cell carcinoma. Oncogene. 40(39):5799-5813 6¡¢Bi X, Lou P, Song Y, Sheng X, Liu R, Deng M, Yang X, Li G, Zhang B, Xue L, Liu Z, Plikus M, Ren F, Gao S, Yuan S, Zhang H, Jiao B, Zhao L*, Yu Z* (2021) Msi1 promotes breast cancer metastasis by regulating invadopodia-mediated extracellular matrix degradation via the Timp3-Mmp9 pathway. Oncogene. 40(29):4832-4845 ÕÐÆ¸¸Úλ¼°ÒªÇó£º 1. ¿ÆÑÐÖúÀí1Ãû£ºÄêÁä¡Ü30ÖÜË꣬¾ßÓÐ˶ʿÑо¿Éú¼°ÒÔÉÏѧÀúºÍѧ룬ÉúÎҽѧ¡¢Ò©Ñ§µÈÏà¹Ø×¨Òµ·½Ïò¡£ÈȰ®¿ÆÑУ¬³Ô¿àÄÍÀÍ£¬¾ßÓÐÍŶÓÐ×÷¾«Éñ£¡ÊìÁ·ÕÆÎÕϸ°ûÅàÑø¡¢»ù±¾µÄÉú»¯ºÍ·Ö×ÓÉúÎïѧʵÑé¼¼ÄÜ£¬µÚ1×÷Õß·¢±íÓÐSCIÂÛÎÄÕßÓÅÏÈ¡£ 2. ½²Ê¦1Ãû£¬²©Ê¿ºó1Ãû£ºÄêÁä¡Ü35ÖÜË꣬¾ßÓв©Ê¿Ñо¿ÉúѧÀúºÍѧ룬Ö×Áö¡¢ÌÇÖ¬´úлºÍ±í¹ÛÒÅ´«µÈÏà¹Ø×¨Òµ·½Ïò¡£ÈȰ®¿ÆÑУ¬³Ô¿àÄÍÀÍ£¬¾ßÓÐÍŶÓÐ×÷¾«Éñ£¡È¡µÃ½ÏºÃµÄÑо¿³É¹û£¨ÒÔµÚ1×÷Õß·¢±íQ1ÇøSCIÂÛÎÄÕßÓÅÏÈ£©²¢ÇҾ߱¸Á¼ºÃµÄ·¢Õ¹Ç±Á¦£»¾ßÓжÀÁ¢µÄ¿ÎÌâÉè¼ÆÄÜÁ¦ºÍÔúʵµÄʵÑé²Ù×÷ÄÜÁ¦£¬Äܹ»ÔÚPIµÄÖ¸µ¼Ï¶ÀÁ¢Õ¹¿ªÑо¿¹¤×÷£¬²¢²ÎÓëÑо¿ÉúµÄÖ¸µ¼¹¤×÷¡£ н³ê´ýÓö£º 1. ´ýÓö²ÎÕÕÌì½òÒ½¿Æ´óѧÏà¹ØÈËÊÂÕþ²ß²¢´ÓÓÅ¡£ 2. Ìṩ¿ÆÑÐÖ¸µ¼£¬²Î¼Ó¹úÄÚÍâѧÊõ»áÒéµÄ»ú»á£¬È«Á¦Ö§³ÖÉêÇë¸÷ÖÖ»ù½ðºÍÈ˲ÅÏîÄ¿¡£ 3. ¿ÆÑÐÖúÀíÒµÎñÊìÁ·Õß¿ÉÍÆ¼ö¼ÌÐø¶Á²© »¶Ó־ȤÏàͶ¡¢ÈȰ®¿ÆÑС¢Çڷܿ̿àµÄ¿ÆÑÐÖúÀí¡¢²©Ê¿ºóºÍ½²Ê¦Ó¦Æ¸Õß¼ÓÈë¿ÎÌâ×飡 |
» ²ÂÄãϲ»¶
Çཷ°ËÄêÒѲ»Ç࣬´ó¼Ò¶¼±»ÕÛÄ¥³ÉɶÑùÁË£¿
ÒѾÓÐ5È˻ظ´
ÇàÄê»ù½ðCÖÕÖ¹
ÒѾÓÐ3È˻ظ´
26É격Ç󲩵¼ÍƼö-Ò£¸ÐͼÏñ´¦Àí·½Ïò
ÒѾÓÐ4È˻ظ´
ÏÞÏî¹æ¶¨
ÒѾÓÐ7È˻ظ´
¾ÈÃüÌû
ÒѾÓÐ8È˻ظ´
Õв©Ê¿
ÒѾÓÐ4È˻ظ´
Î÷ÄϽ»Í¨´óѧ¹ú¼Ò¼¶È˲ÅÍŶÓ2026Ä격ʿÑо¿ÉúÕÐÉú£¨¿¼ºËÖÆ£©¡ª»úе¡¢²ÄÁÏ¡¢Á¦Ñ§·½Ïò
ÒѾÓÐ3È˻ظ´
Ó¢ÎÄ×ÛÊöÊÇ·ñÐèÒªÈóÉ«¼°²éÖØ
ÒѾÓÐ5È˻ظ´
ΪʲônbsÉÏäå ûÓвúÎïµã³öÏÖÄØ
ÒѾÓÐ9È˻ظ´
ÓÐÈË¿´µ½ÎҵĶú»
Ìú³æ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 44.5
- Ìû×Ó: 12
- ÔÚÏß: 49·ÖÖÓ
- ³æºÅ: 35666644
- ×¢²á: 2024-09-23
- רҵ: ¼××´ÏÙ/¼××´ÅÔÏÙ·¢Óý¼°½á¹¹
3Â¥2025-04-16 17:19:12
½ðÔÀÔÀÔÀÒ©
гæ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 43.8
- Ìû×Ó: 15
- ÔÚÏß: 15.8Сʱ
- ³æºÅ: 28618503
- ×¢²á: 2022-02-23
- רҵ: ¿¹Ö×ÁöÒ©ÎïÒ©Àí
2Â¥2025-02-26 10:37:19













»Ø¸´´ËÂ¥